journal article·2022-05-27

Radiolabeled Human Protein-Functionalized Upconversion Nanoparticles for Multimodal Cancer Imaging

Najim Akhtar, Pei-Wen Wu, Chuan Lin Chen, Wen-Yi Chang, Ren-Shyan Liu, Chien Ting Wu, Agnishwar Girigoswami, Surojit Chattopadhyay

ACS Applied Nano Materials· Volume 5· Issue 5
Publisher page

Abstract

Multimodal imaging removes the intrinsic limitations of individual modalities, while the multipurpose nanoagents reduce the toxicity associated with the use of multiple contrast agents. However, limited functionality, inefficient or incompatible targeting, and unknown biodistribution are significant drawbacks for such complicated nanodesigns. We report a biofriendly pentamodal imaging agent with the synergistic dual-targeting ability (passive and active) based on fluoromagnetic NaGdF4:Yb,Er upconverting nanoparticles (UCNPs). Besides the nano-enabled passive targeting, the apo-human serum transferrin protein (Tf) conjugation actively targets the transferrin receptors (TfR) over-expressed on different cancer cells. The radiolabel, 99mTc, chelates in the Tf core increase the radiolabeling efficiency (∼95%) and stability (∼100% for 24 h), enabling efficient single-photon emission computed tomography imaging. Deep-penetrating 980 nm excited UCNPs are inherently active luminescent and photothermal agents enabling fluorescence and photothermal imaging, respectively. The Gd in UCNPs produces a T1-weighted MRI signal, and the Yb helps in computed tomography (CT) as contrast agents. A pentamodal imaging agent (UCNP@Tf-99mTc) with synergistic dual-targeting ability is thus designed. In vitro studies demonstrated receptor-mediated endocytosis and minimal cytotoxicity of the UCNP@Tf-99mTc nanoformulation (>75% cell viability at 1000 ppm). The in vivo biodistribution studies in the mice model under SPECT/CT revealed its near-ideal bioavailability and renal clearance behavior. The MRI investigation on 4 T1 tumor-bearing mice brought direct evidence of passive and synergistic passive-active targeted tumor accumulation of the nanoformulation. The in vivo multimodal tumor imaging (MRI/SPECT/thermal-camera/CT) demonstrates the potency of UCNP@Tf-99mTc as a single replacement for multiple imaging agents and a perfect candidate for the ultramodern Advanced Multimodality Image Guided Operating (AMIGO) suite.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Luminescence Properties of Advanced Materials · Machine Learning in Materials Science

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Institute of Biophotonics, National Yang-Ming Chiao Tung University, Taipei 112, Taiwan

Department of Biomedical Imaging and Radiological Sciences, National Yang Ming Chiao Tung University, Taipei 112, Taiwan

National PET/Cyclotron Center, Nuclear Medicine Department, Taipei Veterans General Hospital, Taipei 112, Taiwan

Nano Device Materials Characterization Division, National Nano Device Laboratories, Hsinchu 300, Taiwan

Faculty of Allied Health Sciences, Chettinad Hospital & Research Institute (CHRI), Chettinad Academy of Research and Education (CARE), Kelambakkam, Chennai 603103, India

Funding

Ministry of Science and Technology, Taiwan

References (63)

Show source-provided references
1. 10.1039/C4CS00293H10.1039/C4CS00293H ↗
2. 10.1039/B922628C10.1039/B922628C ↗
3. 10.1007/s11095-019-2608-510.1007/s11095-019-2608-5 ↗
4. 10.1038/453993a10.1038/453993a ↗
5. 10.1016/S0959-8049(02)00386-610.1016/S0959-8049(02)00386-6 ↗
6. 10.1021/acsabm.9b0003910.1021/acsabm.9b00039 ↗
7. 10.1002/anie.20110144710.1002/anie.201101447 ↗
8. 10.1056/NEJMp100253010.1056/NEJMp1002530 ↗
9. 10.1038/nrclinonc.2009.1810.1038/nrclinonc.2009.18 ↗
10. 10.1007/s12350-011-9490-910.1007/s12350-011-9490-9 ↗
11. 10.7150/thno.1608810.7150/thno.16088 ↗
12. 10.1016/j.addr.2014.07.00910.1016/j.addr.2014.07.009 ↗
13. 10.1039/C2CS15261D10.1039/C2CS15261D ↗
14. 10.1002/adfm.20190388410.1002/adfm.201903884 ↗
15. 10.1158/0008-5472.CAN-08-424210.1158/0008-5472.CAN-08-4242 ↗
16. 10.1039/C8NR03741H10.1039/C8NR03741H ↗
17. 10.1021/acsnano.9b0065310.1021/acsnano.9b00653 ↗
18. 10.1016/j.actbio.2018.03.03510.1016/j.actbio.2018.03.035 ↗
19. 10.1002/anie.20080151810.1002/anie.200801518 ↗
20. 10.1016/j.bios.2020.11211510.1016/j.bios.2020.112115 ↗
21. 10.1021/acsanm.9b0018610.1021/acsanm.9b00186 ↗
22. 10.1039/C8RA07441K10.1039/C8RA07441K ↗
23. 10.1038/s41598-017-13284-510.1038/s41598-017-13284-5 ↗
24. 10.1021/acs.inorgchem.8b0115910.1021/acs.inorgchem.8b01159 ↗
25. 10.1039/C6TB00215C10.1039/C6TB00215C ↗
26. 10.1039/C5RA25304G10.1039/C5RA25304G ↗
27. 10.1021/acs.accounts.5b0007810.1021/acs.accounts.5b00078 ↗
28. 10.1016/j.biomaterials.2003.10.06210.1016/j.biomaterials.2003.10.062 ↗
29. 10.2967/jnumed.112.10804310.2967/jnumed.112.108043 ↗
30. 10.1016/j.biotechadv.2010.11.00710.1016/j.biotechadv.2010.11.007 ↗
31. 10.1039/C7NR03019C10.1039/C7NR03019C ↗
32. 10.1039/C5RA22934K10.1039/C5RA22934K ↗
33. 10.1021/ic00100a02410.1021/ic00100a024 ↗
34. 10.1002/ppsc.20180029410.1002/ppsc.201800294 ↗
35. 10.1021/am508626910.1021/am5086269 ↗
36. 10.2147/IJN.S4556110.2147/IJN.S45561 ↗
37. 10.1021/acsabm.8b0070110.1021/acsabm.8b00701 ↗
38. 10.1073/pnas.150966711210.1073/pnas.1509667112 ↗
39. 10.1021/ja410351h10.1021/ja410351h ↗
40. 10.3390/pharmaceutics1002005710.3390/pharmaceutics10020057 ↗
41. 10.1016/j.biomaterials.2010.09.07110.1016/j.biomaterials.2010.09.071 ↗
42. 10.1016/j.actbio.2016.08.04710.1016/j.actbio.2016.08.047 ↗
43. 10.1038/srep2742110.1038/srep27421 ↗
44. 10.1111/j.1742-7843.2011.00844.x10.1111/j.1742-7843.2011.00844.x ↗
45. 10.3390/md1311681810.3390/md13116818 ↗
46. Pereira M. I. A. · 2020 · 21310.1007/978-1-0716-0463-2_12 ↗
47. 10.1039/C4CS00170B10.1039/C4CS00170B ↗
48. 10.1016/j.pmatsci.2021.10083810.1016/j.pmatsci.2021.100838 ↗
49. 10.1002/cmmi.156510.1002/cmmi.1565 ↗
50. 10.1021/nn405082y10.1021/nn405082y ↗
51. 10.1021/mp800049w10.1021/mp800049w ↗
52. 10.1016/j.ejpb.2013.12.01010.1016/j.ejpb.2013.12.010 ↗
53. 10.1038/nbt134010.1038/nbt1340 ↗
54. 10.1039/D0BM00029A10.1039/D0BM00029A ↗
55. 10.1016/j.talanta.2015.09.05910.1016/j.talanta.2015.09.059 ↗
56. 10.2147/IJN.S14835910.2147/IJN.S148359 ↗
57. Matsumura Y. · Cancer Res. · 1986 · 46 · 6387
58. 10.1007/s40820-020-0396-410.1007/s40820-020-0396-4 ↗
59. 10.1016/j.bbagen.2011.07.01610.1016/j.bbagen.2011.07.016 ↗
60. 10.1158/0008-5472.CAN-20-141410.1158/0008-5472.CAN-20-1414 ↗
61. 10.1021/ar700081510.1021/ar7000815 ↗
62. 10.1002/jlcr.315410.1002/jlcr.3154 ↗
63. 10.1021/acsnano.9b0873710.1021/acsnano.9b08737 ↗